(Reuters) – Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment. The once-daily fixed-dose combination, glecaprevir/pibrentasvir (G/P), was given to HCV patients without cirrhosis and who were new to treatment in three different studies. About 97.5 percent of these patients achieved a high SVR rate, which is the most widely used efficacy endpoint in clinical studies of hepatitis C, representing removal of HCV from the body.
Read the original here:
AbbVie’s hepatitis C treatment shows promise
